Life Sciences, Год журнала: 2022, Номер 300, С. 120565 - 120565
Опубликована: Апрель 21, 2022
Язык: Английский
Molecular Cancer, Год журнала: 2024, Номер 23(1)
Опубликована: Март 22, 2024
Abstract Background Cancer stem-like cell is a key barrier for therapeutic resistance and metastasis in various cancers, including breast cancer, yet the underlying mechanisms are still elusive. Through genome-wide lncRNA expression profiling, we identified that LINC00115 robustly upregulated chemoresistant cancer cells (BCSCs). Methods LncRNA microarray assay was performed to document abundance changes of lncRNAs paclitaxel (PTX)-resistant MDA-MB-231 BCSC (ALDH + ) non-BCSC − ). RNA pull-down immunoprecipitation (RIP) assays were determine binding proteins LINC00115. The clinical significance pathway examined TNBC metastatic lymph node tissues. biological function investigated through gain- loss-of-function studies. molecular mechanism explored sequencing, mass spectrometry, CRISPR/Cas9-knockout system. potential xenograft animal models. Results functions as scaffold link SETDB1 PLK3, leading enhanced methylation PLK3 at both K106 K200 drug-resistant BCSC. decreases phosphorylation HIF1α thereby increases stability. HIF1α, turn, upregulates ALKBH5 reduce m 6 A modification LINC00115, resulting attenuated degradation YTHDF2-dependent A-modified Thus, this positive feedback loop provokes phenotypes enhances chemoresistance triple-negative cancer. inhibitor TTD-IN with ASO sensitizes PTX-resistant response chemotherapy model. Correlative SETDB1, prognostic cancers. Conclusions Our findings uncover critical regulator highlight targeting strategy chemotherapeutic resistant
Язык: Английский
Процитировано
18
Cell Proliferation, Год журнала: 2020, Номер 54(2)
Опубликована: Дек. 13, 2020
Triple-negative breast cancer (TNBC) is a type of that has higher risk distant recurrence and metastasis, leading to relatively aggressive biological behaviour poor outcome. So far, the clinical management TNBC challenging because its heterogeneity paucity specific targeted therapy. Recently, various studies have identified lot differently expressed long non-coding RNAs (lncRNAs) in TNBC. Those lncRNAs been reported play important roles multistep process tumorigenesis. Here, we review characteristics lncRNAs, present current state knowledge concerning expression, function regulation Accumulating explored potential lncRNAs-based therapeutics TNBC, including techniques genetic modification using antisense oligonucleotides, locked nucleic acid RNA nanotechnology. In review, also discuss future prospects about development lncRNA-based strategies for patients.
Язык: Английский
Процитировано
68
Frontiers in Molecular Biosciences, Год журнала: 2022, Номер 9
Опубликована: Май 5, 2022
Background: Necroptosis has been an alternatively identified mechanism of programmed cancer cell death, which plays a significant role in cancer. However, research about necroptosis-related long noncoding RNAs (lncRNAs) are still few. Moreover, the potentially prognostic value lncRNAs and their correlation with immune microenvironment remains unclear. The present study aimed to explore potential relationship triple-negative breast (TNBC). Methods: RNA expression matrix patients TNBC was obtained from Cancer Genome Atlas (TCGA) Gene Expression Omnibus (GEO) databases. Finally, 107 GSE58812, 159 TCGA, 143 GSE96058 were included. Necroptosis-related screened by Cox regression Pearson analysis genes. By LASSO analysis, nine employed, necroptosis index (CNI) established; then, we evaluated its value, clinical significance, pathways, infiltration, chemotherapeutics efficacy. Results: Based on CNI divided into high- low-CNI groups, high had worse prognosis, more lymph node metastasis, larger tumor (p < 0.05). receiver operating characteristic (ROC) showed that signature performed well. result infiltration proportion different further explained low immunogenicity, leading poor therapeutic outcomes. found differences IC50 values various chemotherapeutic drugs two might provide reference make personalized chemotherapy for them. Conclusion: novel marker could not only precisely predict survival probability but also demonstrate antitumor immunity drug sensitivity.
Язык: Английский
Процитировано
38
Cellular and Molecular Life Sciences, Год журнала: 2022, Номер 79(1)
Опубликована: Янв. 1, 2022
Язык: Английский
Процитировано
37
Cancer Cell International, Год журнала: 2025, Номер 25(1)
Опубликована: Янв. 20, 2025
This narrative review explores the link between breast cancer and night shift work in nurses, focusing on genetic epigenetic factors. Breast disproportionately affects women globally, is increasingly recognized as a potential risk factor. Nurses who consecutive overnight shifts face elevated risks due to disruptions their circadian rhythms. Studies suggest that working six or more successive shifts, particularly over five years more, may increase risk. hypothesizes sleep-wake cycle, such changes melatonin production telomere length, could contribute susceptibility. Currently, there limited evidence support this hypothesis. However, it plausible alterations, including genes like ER HER2, heighten for nurses. These alterations involve variations DNA methylation, critical cancer-related genes. We highlight various influence increased Further research needed explore underlying mechanisms contributing factors association.
Язык: Английский
Процитировано
1
Annals of Translational Medicine, Год журнала: 2023, Номер 11(2), С. 119 - 119
Опубликована: Янв. 1, 2023
Growth arrest-specific 5 (GAS5) is a long noncoding RNA (lncRNA) that regulates cell viability. GAS5 lncRNA has been shown to decrease colorectal and breast cancer carcinogenesis. Although the function mechanisms related in development of ovarian (OC) remains unclear. The goal this study was clarify essential functions regulating OC progression its underlying mechanism.Relative levels normal tissues were identified by quantitative real-time polymerase chain reaction (qRT-PCR). regulatory effects on proliferation apoptosis SK-OV-3 cells evaluated. Moreover, bioinformatics tools used predict novel target [microRNA (miRNA)] GAS5. To explore key GAS5/miRNA-23a/WT1 loop mediating progression, we performed functional experiments dual-luciferase reporter (DLR) gene assessment.Downregulation found OC, which positively correlated with poor prognosis. In addition, lower expression accelerated migration demonstrated percentage vitro experiments. It acts as molecular sponge for miR-23a cells. Additionally, WT1 detected cells, through sponging miR-23a, regulated expression. Rescue tests enhancing outputs miR-23a-WT1 axis reversed impacts silencing OC.The GAS5/miR-23a/WT1 cascade participate OC. also decreases upregulating attenuating suggesting it could be an advantageous therapeutic intervention.
Язык: Английский
Процитировано
13
Frontiers in Chemistry, Год журнала: 2021, Номер 9
Опубликована: Дек. 24, 2021
Hypoxia is not only the reason of tumor metastasis but also enhances spread cancer cells from original site, which results in recurrence. Herein, we developed a self-assembled RNA hydrogel that efficiently delivered synergistic DNA CpG and short hairpin (shRNA) adjuvants, as well MnO2 loaded-photodynamic agent chlorine e6 (MnO2@Ce6), chemotherapy drug doxorubicin (DOX) into MDA-MB-231cells. The consists one tumour suppressor miRNA (miRNA-205) anti-metastatic (miRNA-182), both showed an outstanding effect synergistically abrogating tumours. would be dissociated by endogenous Dicer enzyme to release loaded therapeutic molecules, meantime induce decomposition H2O2 relieve hypoxia. As result, remarkable achieved through combined chemo-photodynamic therapy, simultaneously triggers series anti-tumor immune responses. Besides, carrier modified aptamer targeted MDA-MB-231 has advantages good biocompatibility low cytotoxicity. This strategy could implemented design any other microRNA (miRNA) carrier, with treatment methods treat human cancer, thereby overcoming limitations current therapies.
Язык: Английский
Процитировано
24
Diagnostics, Год журнала: 2023, Номер 13(11), С. 1949 - 1949
Опубликована: Июнь 2, 2023
Triple-negative breast cancer (TNBC) is a specific subtype of lacking hormone receptor expression and HER2 gene amplification. TNBC represents heterogeneous cancer, characterized by poor prognosis, high invasiveness, metastatic potential, tendency to relapse. In this review, the molecular subtypes pathological aspects triple-negative are illustrated, with particular attention biomarker characteristics TNBC, namely: regulators cell proliferation migration angiogenesis, apoptosis-regulating proteins, DNA damage response, immune checkpoints, epigenetic modifications. This paper also focuses on omics approaches exploring such as genomics identify cancer-specific mutations, epigenomics altered landscapes in cells, transcriptomics explore differential mRNA protein expression. Moreover, updated neoadjuvant treatments for mentioned, underlining role immunotherapy novel targeted agents treatment TNBC.
Язык: Английский
Процитировано
11
International Journal of Biological Macromolecules, Год журнала: 2024, Номер 274, С. 132730 - 132730
Опубликована: Июнь 12, 2024
Язык: Английский
Процитировано
4
Non-coding RNA Research, Год журнала: 2021, Номер 6(4), С. 174 - 186
Опубликована: Дек. 1, 2021
Long non-coding RNAs (LncRNAs) play a vital role in the process of malignant transformation. In breast cancer (BC), lncRNAs field is currently under intensive investigations. Yet, as promising diagnostic and/or prognostic biomarkers and therapeutic target/tool among BC patients still needs special focus from biomedical scientists. BC, triple negative (TNBC) are unlucky group they always represented with worst prognosis highest mortality rates. For that reason, on TNBC associated was addressed this review. Colon cancer-associated transcript 1 (CCAT-1) newly discovered oncogenic lncRNA has been emerged biomarker for diagnosis, interventions multiple malignancies showed differential expression patients. review, authors shed light onto general specific functional activities, molecular mechanisms, competing endogenous ncRNA CCAT-1 TNBC.
Язык: Английский
Процитировано
23